Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in CIDP
NCT03861481Phase 2Completed
- Sponsor
- UCB
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) comparing Rozanolixizumab with Placebo (2 arms). Primary endpoint: Inflammatory Rasch-built Overall Disability Scale at 13 weeks. Started Mar 2019; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT03861481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861481.